Sarepta Therapeutics Inc (NASDAQ:SRPT) target price raised to $48.00, issued a ratings update earlier today by SunTrust Banks Inc.
- Updated: September 20, 2016
Reporting as possible downside of -0.14%, SunTrust Banks Inc. bumped up the price target of Sarepta Therapeutics Inc (NASDAQ:SRPT) to $48.00
Boasting a price of $55.79, Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 13.87% higher on the day. With the last stock price close up 164.46% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Sarepta Therapeutics Inc has recorded a 50-day average of $27.32 and a two hundred day average of $21.07. Volume of trade was up over the average, with 21,083,696 shares of SRPT changing hands over the typical 3,322,250
With a total market value of $0, Sarepta Therapeutics Inc has with a one year low of $8.00 and a one year high of $56.80 .
A total of 13 equity analysts have released a ratings update on SRPT. Three equity analysts rating the company a strong buy, one equity analyst rating the company a buy, five equity analysts rating the company a hold, four equity analysts rating the company a underperform, and finally one equity analyst rating the company a sell with a one year target of $20.77.
Brief Synopsis About Sarepta Therapeutics Inc (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.